Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.
Also called NCT02107898
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 216 participants
- Sponsor
- Registry
-
NCT02107898
-
- Other papers using this trial's data
- Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT02107898. Randomized; quadruple masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-01 (actual). Results posted on 2016-01-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02107898- Content hash
01b62ee5d0027c14c3cc7e952a23390aa07480276b81c541ee777b3676ac6005